Aktienanalyse zu Evotec SE (EVO)EVOEvotec SE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others. It operates in the Healthcare sector.

Evotec SE is not a good buy right now due to significant revenue declines and negative analyst sentiment. The stock is currently priced at $1.91, down 39.94% year-to-date, and has an RSI of 41.068, indicating a lack of momentum. The company has reported a decrease in revenues, with Q2 2026 revenues down 16.2% year-over-year, and a revised full-year revenue guidance of €570 to €610 million, significantly lower than the previous year's €788.4 million. The main risk is the forward P/E ratio of 53.4759, indicating potential overvaluation given the company's current performance.